GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » Capex-to-Operating-Income

Maat Pharma (XPAR:MAAT) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Maat Pharma's Capital Expenditure for the six months ended in Dec. 2024 was €-0.58 Mil. Its Operating Income for the six months ended in Dec. 2024 was €-15.67 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Maat Pharma Capex-to-Operating-Income Historical Data

The historical data trend for Maat Pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma Capex-to-Operating-Income Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Maat Pharma's Capex-to-Operating-Income

For the Biotechnology subindustry, Maat Pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maat Pharma's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maat Pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Maat Pharma's Capex-to-Operating-Income falls into.


;
;

Maat Pharma Capex-to-Operating-Income Calculation

Maat Pharma's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.753) / -28.429
=N/A

Maat Pharma's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.581) / -15.673
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maat Pharma  (XPAR:MAAT) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Maat Pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Maat Pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Maat Pharma Business Description

Traded in Other Exchanges
Address
70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma Headlines

No Headlines